Elaidic acid

Elaidic acid is an orally active trans fatty acid. Elaidic acid enhances the stemness of colorectal cancer cells by activating the Wnt/ERK1/2 pathway, thereby promoting cell proliferation, invasion and metastasis, and inhibiting apoptosis. Elaidic acid also inhibits the growth of Lactobacillus and alters the cell surface hydrophobicity of Lactobacillus. Elaidic acid reduces basal 2-deoxyglucose uptake in muscle cells and adipocytes. Elaidic acid can be used in research on colorectal cancer, insulin and other related areas^[1][2][3]. In Vitro:Elaidic acid (0-35 μM; 24-48 h) dose-dependently promotes the growth, reduces the apoptosis and enhances the invasive ability of CT26 and HT29 colorectal cancer cells^[1].
Elaidic acid (35 μM; 1 week) enhances the sphere-forming capacity of CT26 colorectal cancer cells under concurrent treatment, pre-treatment, and hypoxic conditions^[1].
Elaidic acid upregulates the expression of stem cell markers (nucleostemin, CD133, Oct4) and dedifferentiation marker (c-Myc), while downregulates the expression of differentiation markers (MUC1, MUC2, CDX2) in CT26 colorectal cancer spheres^[1].
Elaidic acid (0-500 mg/L; 0-24 h) inhibits the growth of L. rhamnosus, L. paracasei, L. zeae, <L. acidophilus and L. plantarum, but exerts no effect on the growth of L. casei^[2].
Elaidic acid (200 mg/L; 0-24 h) reduces the cell surface hydrophobicity of L. paracasei and L. casei^[2].
Elaidic acid (20-500 μM; 24 h) dose-dependently upregulates the mRNA level of TNF-α, decreases the mRNA level of IL-15, and does not enhance insulin-stimulated glucose uptake in differentiated C2C12 myotubes^[3]. In Vivo:Elaidic acid (10 mg/mouse; i.p.) promotes the growth and metastasis of CRC tumors in BALB/c mice and upregulates the expression of tumor differentiation markers^[1].
Elaidic acid (0-0.2 mg/kg; i.g.; every 7 days; 4 weeks) increases the number of liver CRC metastatic foci and CD133-positive cells in BALB/c mice^[1].